National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Mifamurtide (Meptact®) for the treatment of osteosarcoma.

Rapid Review

Commenced Completed Outcome
22/06/2010 13/07/2010 Full Pharmacoeconomic Evaluation Recommended

A formal PEA is required to demonstrate value for money prior to reimbursement.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.